2019
Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking
Bold KW, Zweben A, Fucito LM, Piepmeier ME, Muvvala S, Wu R, Gueorguieva R, O'Malley SS. Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking. Alcohol Clinical And Experimental Research 2019, 43: 937-944. PMID: 30817018, PMCID: PMC7039307, DOI: 10.1111/acer.13994.Peer-Reviewed Original ResearchConceptsEnd of treatmentAlcohol use disorderHeavy drinking daysMedical managementCigarette smokingComorbid cigarette smokingUse disordersDrinking daysCo-occurring alcohol use disorderHigh ratePlacebo-controlled trialBetter clinical outcomesAssessment of alcoholPercent of participantsVarenicline treatmentClinical outcomesSmoking abstinenceParallel groupClinical trialsTimeline FollowVareniclineSmoking behaviorAlcohol treatmentPosttreatment outcomesMultisite trial
2018
Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial
O’Malley S, Zweben A, Fucito LM, Wu R, Piepmeier ME, Ockert DM, Bold KW, Petrakis I, Muvvala S, Jatlow P, Gueorguieva R. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA Psychiatry 2018, 75: 129-138. PMID: 29261824, PMCID: PMC5838706, DOI: 10.1001/jamapsychiatry.2017.3544.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMedical managementUse disordersCigarette smokingWeek 9Varenicline tartrateEfficacy of vareniclinePlacebo-controlled trialBehavioral health risksComorbid cigarette smokingRace/ethnicityAlcohol dependence criteriaSmoking 2Medication adherenceOutpatient clinicPlacebo pillsMean ageEligible participantsSmoking abstinenceClinical trialsParallel groupPlaceboMAIN OUTCOMEVareniclineWeek 13
2017
The clinical utility of the Medication Adherence Questionnaire (MAQ) in an alcohol pharmacotherapy trial
Zweben A, Piepmeier M, Fucito L, O'Malley S. The clinical utility of the Medication Adherence Questionnaire (MAQ) in an alcohol pharmacotherapy trial. Journal Of Substance Use And Addiction Treatment 2017, 77: 72-78. PMID: 28476276, PMCID: PMC5480370, DOI: 10.1016/j.jsat.2017.04.001.Peer-Reviewed Original ResearchConceptsMedication Adherence QuestionnaireMedication adherenceAdherence QuestionnaireMedical managementTreatment attendanceAlcohol pharmacotherapy trialsAlcohol-dependent smokersTreatment satisfaction ratingsBrief psychosocial treatmentsAlcohol use disorderMM sessionsPharmacology treatmentBaseline characteristicsBaseline demographicsAlcohol pharmacotherapyMedication nonadherenceUnintentional nonadherenceAdherence groupPharmacotherapy trialsDependent smokersTreatment adherenceSingle administrationPatient ratingsTreatment periodClinical utility
2012
Cigarette Smoking Predicts Differential Benefit from Naltrexone for Alcohol Dependence
Fucito LM, Park A, Gulliver SB, Mattson ME, Gueorguieva RV, O'Malley SS. Cigarette Smoking Predicts Differential Benefit from Naltrexone for Alcohol Dependence. Biological Psychiatry 2012, 72: 832-838. PMID: 22541040, PMCID: PMC3410039, DOI: 10.1016/j.biopsych.2012.03.023.Peer-Reviewed Original ResearchConceptsCigarette smokingAlcohol dependenceBehavioral interventionsAlcohol-dependent smokersCombination of medicationsBaseline demographic differencesPoor treatment outcomesPoor treatment responseDrinking outcomesBetter drinking outcomesSevere alcohol dependenceAlcohol-dependent individualsCigarette intakeAlcohol use outcomesMedical managementPharmacological treatmentTreatment outcomesTreatment responseSmokingSmokersCOMBINE StudyAlcoholism typologyDrinking-related variablesTreatment assignmentNonsmokers